REGN-13335(REGN-13335) - 药物靶点：PDGFB_在研适应症：心血管疾病，代谢性疾病_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

REGN 13335、REGN13335

靶点

PDGFB

作用方式

抑制剂

作用机制

PDGFB抑制剂(血小板衍生生长因子B亚基抑制剂)

治疗领域

心血管疾病内分泌与代谢疾病

在研适应症

心血管疾病代谢性疾病

非在研适应症-

原研机构

Regeneron Pharmaceuticals, Inc.

在研机构

Regeneron Pharmaceuticals, Inc.

非在研机构-

权益机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看时间轴

关联

2

项与 REGN-13335 相关的临床试验

NCT07318597

/ Not yet recruiting临床2期

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN13335, an Anti-PDGF-B Monoclonal Antibody, in Adults With Pulmonary Arterial Hypertension

This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH). The aim of the study is to see how safe and effective REGN13335 is in participants with PAH who are taking other PAH medicines.
The study is looking at several other research questions, including:
* What side effects may happen from taking REGN13335
* How much REGN13335 is in the blood at different times
* Whether the body makes antibodies against REGN13335 (which could make REGN13335 less effective or could lead to side effects)

开始日期2026-01-29

申办/合作机构

Regeneron Pharmaceuticals, Inc.

NCT06137482

/ Completed临床1期

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenously or Subcutaneously Administered REGN13335, a Platelet-Derived Growth Factor-B Antagonist, in Healthy Adult Participants

This study is researching an experimental drug called REGN13335. This is the first time that REGN13335 will be given to people. This study will enroll healthy adults.
The aim of the study is to see how safe and tolerable REGN13335 is in healthy volunteers.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug
* How much study drug is present in the blood of study participants at different times
* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

开始日期2023-12-06

申办/合作机构

Regeneron Pharmaceuticals, Inc.

100 项与 REGN-13335 相关的临床结果

登录后查看更多信息

100 项与 REGN-13335 相关的转化医学

登录后查看更多信息

100 项与 REGN-13335 相关的专利（医药）

登录后查看更多信息

100 项与 REGN-13335 相关的药物交易

登录后查看更多信息